156 related articles for article (PubMed ID: 19573485)
1. Can lithium or valproate untie tangles in Alzheimer's disease?
Tariot PN; Aisen PS
J Clin Psychiatry; 2009 Jun; 70(6):919-21. PubMed ID: 19573485
[No Abstract] [Full Text] [Related]
2. Alzheimer's disease: Mental plaque removal.
De Strooper B; Woodgett J
Nature; 2003 May; 423(6938):392-3. PubMed ID: 12761533
[No Abstract] [Full Text] [Related]
3. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
4. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
5. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
6. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
Loy R; Tariot PN
J Mol Neurosci; 2002 Dec; 19(3):303-7. PubMed ID: 12540056
[TBL] [Abstract][Full Text] [Related]
8. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.
Chalmers KA; Wilcock GK; Vinters HV; Perry EK; Perry R; Ballard CG; Love S
J Neurol; 2009 May; 256(5):717-20. PubMed ID: 19240967
[TBL] [Abstract][Full Text] [Related]
9. Treatments for Alzheimer's disease emerge.
Selkoe DJ
Science; 2021 Aug; 373(6555):624-626. PubMed ID: 34353940
[No Abstract] [Full Text] [Related]
10. [Alzheimer's disease: cellular and molecular aspects].
Octave JN; Pierrot N
Bull Acad Natl Med; 2008 Feb; 192(2):323-31; discussion 331-2. PubMed ID: 18819686
[TBL] [Abstract][Full Text] [Related]
11. Looking for novel ways to treat the hallmarks of Alzheimer's disease.
Stewart AJ; Fox A; Morimoto BH; Gozes I
Expert Opin Investig Drugs; 2007 Aug; 16(8):1183-96. PubMed ID: 17685868
[TBL] [Abstract][Full Text] [Related]
12. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease.
Alvarez G; Muñoz-Montaño JR; Satrústegui J; Avila J; Bogónez E; Díaz-Nido J
Bipolar Disord; 2002 Jun; 4(3):153-65. PubMed ID: 12180271
[TBL] [Abstract][Full Text] [Related]
13. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?
Citrome L
J Clin Psychiatry; 2009 Jun; 70(6):932-3. PubMed ID: 19573487
[No Abstract] [Full Text] [Related]
14. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
15. Treating the lesions, not the disease.
Zhu X; Avila J; Perry G; Smith MA
Am J Pathol; 2007 May; 170(5):1457-9. PubMed ID: 17456753
[No Abstract] [Full Text] [Related]
16. Mechanism-based treatments for Alzheimer's disease.
Davies P; Koppel J
Dialogues Clin Neurosci; 2009; 11(2):159-69. PubMed ID: 19585951
[TBL] [Abstract][Full Text] [Related]
17. A new kind of Alzheimer's disease plaque.
Baum L; Ng HK
Adv Anat Pathol; 1998 May; 5(3):170-4. PubMed ID: 9868523
[No Abstract] [Full Text] [Related]
18. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.
Qing H; He G; Ly PT; Fox CJ; Staufenbiel M; Cai F; Zhang Z; Wei S; Sun X; Chen CH; Zhou W; Wang K; Song W
J Exp Med; 2008 Nov; 205(12):2781-9. PubMed ID: 18955571
[TBL] [Abstract][Full Text] [Related]
19. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
20. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
